Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1996 1
1998 1
2001 4
2002 3
2003 4
2004 4
2005 3
2006 4
2007 9
2008 6
2009 10
2010 24
2011 26
2012 28
2013 28
2014 34
2015 40
2016 56
2017 63
2018 72
2019 87
2020 62
2021 79
2022 54
Text availability
Article attribute
Article type
Publication date

Search Results

633 results
Results by year
Filters applied: . Clear all
Page 1
Circular RNAs in immune responses and immune diseases.
Chen X, Yang T, Wang W, Xi W, Zhang T, Li Q, Yang A, Wang T. Chen X, et al. Among authors: xi w. Theranostics. 2019 Jan 1;9(2):588-607. doi: 10.7150/thno.29678. eCollection 2019. Theranostics. 2019. PMID: 30809295 Free PMC article. Review.
Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-κB repressing factor.
Chen XJ, Zhang WN, Chen B, Xi WD, Lu Y, Huang JY, Wang YY, Long J, Wu SF, Zhang YX, Wang S, Li SX, Yin T, Lu M, Xi XD, Li JM, Wang KK, Chen Z, Chen SJ. Chen XJ, et al. Among authors: xi wd. Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2220-2225. doi: 10.1073/pnas.1818539116. Epub 2019 Jan 18. Proc Natl Acad Sci U S A. 2019. PMID: 30659143 Free PMC article.
Bioengineering methods for organoid systems.
Saleh J, Mercier B, Xi W. Saleh J, et al. Among authors: xi w. Biol Cell. 2021 Dec;113(12):475-491. doi: 10.1111/boc.202000119. Epub 2021 Oct 13. Biol Cell. 2021. PMID: 34580889 Review.
Neural Circuits for Sleep-Wake Regulation.
Wu Y, Wang L, Yang F, Xi W. Wu Y, et al. Among authors: xi w. Adv Exp Med Biol. 2020;1284:91-112. doi: 10.1007/978-981-15-7086-5_8. Adv Exp Med Biol. 2020. PMID: 32852742 Review.
Antioxidant activity of Citrus fruits.
Zou Z, Xi W, Hu Y, Nie C, Zhou Z. Zou Z, et al. Among authors: xi w. Food Chem. 2016 Apr 1;196:885-96. doi: 10.1016/j.foodchem.2015.09.072. Epub 2015 Sep 21. Food Chem. 2016. PMID: 26593569 Review.
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X. Xia Y, et al. Among authors: xi w. J Immunother Cancer. 2022 Apr;10(4):e004656. doi: 10.1136/jitc-2022-004656. J Immunother Cancer. 2022. PMID: 35379737 Free PMC article. Clinical Trial.
633 results